Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Delcath Systems Inc.102 enrolled

Overview

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

The study will consist of 3 phases: a screening phase, treatment phase, and follow-up phase. Screening Phase: Screening assessments will be conducted within 28 days prior to the eligibility date to determine each patient's overall eligibility and baseline characteristics. These assessments will include medical history, physical examination, Eastern Cooperative Oncology Group (ECOG) performance status (PS), 12 lead electrocardiogram (ECG), echocardiogram (ECHO), vital signs, full hematology and biochemistry, Quality of Life questionnaire, radiologic assessments of baseline disease status and concomitant medications. For patients with a history of liver surgery or major vasculature surgery, an angiogram evaluation of their vasculature will be performed for compatibility for Percutaneous Hepatic Perfusion (PHP) prior to confirming eligibility. Eligibility date: This is the date on which all screening assessments have been completed and the patient is determined to be eligible for the trial. Treatment Phase: Eligible patients will be treated with Melphalan/HDS 3.0 mg/kg Ideal Body Weight (IBW) and must begin treatment within 14 days being eligible. Melphalan/HDS treatment, patients will receive up to 6 treatments. Each treatment cycle consists of 6 weeks with an acceptable delay for another 2 weeks before the next planned treatment to allow for recovery of melphalan-related toxicity, if needed. Tumor response will be assessed every 12 weeks (+ 2 weeks) until disease progression. If the patient receives only 1 treatment, the disease assessment scans will be conducted 12 weeks after the date of the first treatment. The assessment scans will be reviewed by an Independent Review Committee (IRC), also referred to as Independent Central Review. At any time when progressive disease (PD) is observed, the patient will be removed from further study treatment and followed until death. Melphalan/HDS treatment will also be discontinued in the event that recovery from treatment related toxicity requires more than 8 weeks from last treatment. An end-of-treatment visit will be conducted approximately 6 to 8 weeks following the final study treatment. Ongoing treatment related adverse events (AEs) at the end-of-treatment visit will be followed until the severity is within one of the following parameters (1) Symptoms are resolved or return to baseline; (2) CTCAE Grade \< 1 or can be explained; (3) patient death. The maximum possible duration of the study treatment for any patient will be 12 months. NOTE: Active Melphalan/HDS patients (currently in treatment) on PHP-OCM-301 will continue treatment on PHP-OCM-301A following the re-consenting process. NOTE: Patients on PHP-OCM-301 that have completed treatment and are entering or are already in the follow-up phase will be followed-up for survival and disease progression (as applicable) on PHP-OCM-301A following the re-consenting process. Follow-up Phase: Once the patient has completed the end-of-treatment (EOT) visit in accordance with the schedule of events they will enter the follow-up phase. If the disease has not progressed at the EOT (Section 6.2), the patient will need to continue with disease assessment visits every 12 weeks (+ 2 weeks) until disease progression is documented. If the disease has progressed before or at the EOT their follow-up is to be by phone every 3 months for survival status until death. Patients will be monitored, following the completion of study treatment, for the development of myelodysplasia and secondary leukemia.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

102

Conditions

Melanoma, Ocular

Interventions

Melphalan/HDSCOMBINATION_PRODUCT

Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Male or female patients ≥ 18 years of age. 2. Patients must weigh ≥ 35 kg (due to possible size limitations with respect to percutaneous catheterization of the femoral artery and vein using the Delcath Hepatic Delivery System). 3. 50% or less histologically or cytologically-proven ocular melanoma metastases in the parenchyma of the liver. 4. Disease in the liver must be measurable by computed tomography (CT) and/or magnetic resonance imaging (MRI). 5. Evidence of limited extrahepatic disease on preoperative radiological studies is acceptable if the life threatening component of disease is in the liver. Limited extrahepatic disease is defined in this protocol as follows: metastasis in bone, subcutaneous, lung or lymph nodes that is amenable to resection or radiation and has a defined treatment plan. Patients with extra-hepatic tumor burden which does not have a defined treatment plan (i.e. monitor or is unable to be resected or radiated) must not be included in the trial. 6. Scans used to determine eligibility (CT scan of the chest/abdomen/pelvis and MRI of the liver) must be performed within 28 days prior to randomization. An MRI of the liver is required at screening to validate that CT accurately reflects the extent of disease in the liver. For patients with MRI intolerance, a 3-phase liver CT is to be done in place of liver MRI. 7. Patients must not have chemotherapy, radiotherapy, chemoembolization, radioembolization, or immunoembolization for their malignancy within 30 days prior to treatment and must have recovered from all side effects of therapeutic and diagnostic interventions except those listed in Appendix B of the study protocol. 8. Patients receiving anti programmed cell death protein 1 (PD-1) immunotherapy such as pembrolizumab or nivolumab, or human cytotoxic T-lymphocyte antigen 4 blocking antibody such as ipilimumab should wait 8 weeks before Melphalan/HDS treatment. 9. Patients must have an ECOG PS of 0-1 at screening and on the day prior to treatment. 10. Patients must have adequate hepatic function as evidenced by total serum bilirubin ≤ 1.5 x the upper limit of normal (ULN) and a prothrombin time (PT) within 2 seconds of the upper normal limit. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) must be ≤ 2.5 x ULN. 11. Patients must have a platelet count \> 100,000/µL, hemoglobin ≥ 10.0 gm/dL, white blood cell count (WBC) \> 2,000/uL, absolute neutrophil count (ANC) ≥ 1.5 x 109/L, and a serum creatinine ≤ 1.5 mg/dL unless the measured creatinine clearance is \> 40 mL/min/1.73 m2. 12. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test (β-human chorionic gonadotropin) within 7 days prior to randomization. 13. Provided signed informed consent. Exclusion Criteria: 1. Patients with Child-Pugh Class B or C cirrhosis or with evidence of portal hypertension by history, endoscopy, or radiologic studies. 2. Those with New York Heart Association functional classification II, III or IV active cardiac conditions, including unstable coronary syndromes (unstable or severe angina, recent myocardial infarction), worsening or new-onset congestive heart failure, significant arrhythmias and severe valvular disease must be evaluated for risks of undergoing general anesthesia. 3. History or evidence of clinically significant pulmonary disease that precludes the use of general anesthesia. 4. Women of childbearing potential (WOCBP) i.e. fertile meaning not permanently sterilized and having had a menstrual period within the past 12 months) unable to undergo hormonal suppression to avoid menstruation during treatment. 5. WOCBP and fertile males (not permanently sterile by bilateral orchidectomy) unwilling or unable to use highly effective contraception method for consent to at least 6 months after the last administration of study treatment (e.g. combined hormonal contraception; progestogen-only hormonal contraception; Intrauterine device, intrauterine hormone-releasing system; bilateral tubal occlusion, vasectomized partner or sexual abstinence). 6. Females that are pregnant or breastfeeding patients 7. Patients taking immunosuppressive drugs; however, oral corticosteroids ≤ 10 mg/day are allowed. 8. Patients who are unable to be temporarily removed from chronic anti-coagulation therapy. 9. Patients with active bacterial infections with systemic manifestations (malaise, fever, leucocytosis) are not eligible until completion of appropriate therapy. 10. Patients with severe allergic reaction to iodine contrast, which cannot be controlled by premedication with antihistamines and steroids (because a hepatic angiogram is needed for the Delcath system procedure). 11. Patients with a history of or known hypersensitivity to melphalan or the components of the Melphalan/HDS system. 12. Patients with latex allergy. 13. Patients with a history of hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia. 14. Patients with a history of bleeding disorders or evidence of intracranial abnormalities which would put them at risk for bleeding with anti-coagulation (e.g., strokes, active metastases). 15. Patients with a history of gastrinoma, hepatic vasculature incompatible with perfusion, hepatofugal flow in the portal vein or known unresolved venous shunting. 16. Known varices at risk of bleeding, including medium or large esophageal or gastric varices, or active peptic ulcer. 17. Patients with prior Whipple's procedure. 18. Patients with brain metastases or presence of other intracranial lesions at risk for bleeding by history or baseline radiologic imaging. 19. Patients with active liver infection, including Hepatitis B and Hepatitis C infection. Patients with anti-hepatitis B core antibody (HBc) positive, or hepatitis B surface antigen (HBsAg) but DNA negative are exception(s). 20. Uncontrolled endocrine disorders including diabetes mellitus, hypothyroidism, or hyperthyroidism. 21. Received any investigational agent for any indication within 30 days prior to first treatment. 22. Not recovered from side effects of prior therapy to ≤ Grade 1 (according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 4.03). Certain side effects that are unlikely to develop into serious or life-threatening events (e.g. alopecia) are allowed at \> Grade 1. 23. Cancers other than ocular melanoma for which the patient is currently under treatment or still deemed not to be cancer free.

Locations (24)

University of Arizona

Tucson, Arizona, United States

Outcomes

Primary Outcomes

Objective Response Rate (ORR) as determined by Independent Central Review Committee

ORR (complete or partial response)

Time frame: Patients will be assessed for ORR from baseline through completion of treatment. [assessed up to 36 months]

Secondary Outcomes

Duration of Response (DOR) as determined by Independent Central Review Committee

Duration of Response (DOR) is defined as the time from first documented confirmed response of CR or PR based on RECIST v1.1 determined by the IRC to the first documented progression or death due to any cause.

Time frame: From time of 1st treatment until there is evidence of disease progression [assessed up to 36 months]

Disease Control Rate (DCR) determined by Independent Central Review Committee

DCR is defined as the proportion of patients with a best overall response of CR of any duration, PR of any duration, or stable disease (SD) for a minimum of 12 weeks from the eligibility date for PHP-OCM-301A patients (and randomization date for PHP-OCM-301 patients)

Time frame: ORR will be assessed every 10-14 weeks from the start of 1st treatment and continues until the earlier of either when there is evidence of disease progression or 1 year from 1st treatment.

Overall Survival

Overall Survival will be measured from the eligibility date for PHP-OCM-301A patients (and randomization date for PHP-OCM-301 patients) to the date of death (included all-cause mortality).

Time frame: From the start of the study to the date the patient was last known alive. [assessed up to 36 months]

Progression-Free Survival

PFS is defined as the time from the eligibility date for PHP-OCM-301A patients (and randomization date for PHP-OCM-301 patients) to the first occurrence of disease progression (either hepatic or extra-hepatic), as determined by the investigator and Independent Central Review Committee assessments using RECIST (version 1.1), or death from any cause.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.